ClinicalTrials.gg
CompletedNCT06030362Updated Oct 9, 2026

Probiotic Intervention Study

An interventional study of Probiotic and Placebo in Obesity and Food Addiction, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Treatment

How we know

Updated Oct 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing probiotic in Obesity — 9 open to participants now, 12 under way, none of them phase 3. Probiotic · Obesity.

Enrollment
7th of 33
106 · median 76
Started
2023
with 3 others
No phase
28 of 33
7 open now
Registered
17th of 33
by date

Among the 33 studies testing probiotic in Obesity, this one is the 7th largest by enrollment, is one of 4 that started in 2023, is one of 28 with no phase, and was the 17th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 33 studies testing probiotic in Obesity are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About probiotic

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing probiotic in Obesity, or all of them as a file.
02

Study summary

The current standard of care for obesity is the optimal management of comorbid conditions such as diabetes and hyperlipidemia, and counseling on diet, weight loss, or increased physical activity programs. However, lifestyle, diet, and behavioral interventions may provide between 7-10% reduction in initial weight and even fewer with long-term weight loss. In severely obese patients (BMI>40 or BMI>35 with comorbidities), bariatric surgery is also a potential treatment, but there is a high barrier for patients to undergo surgery for weight loss. These barriers include an aversion to major abdominal surgery, long recovery time, potential risk of vitamin deficiency, and risk for abdominal pain. For these reasons, there is a paramount need for other treatments for obesity and for food addiction.

The current standard of care for obesity and food addiction is difficult to implement and lacks sustained efficacy. Most struggle to complete treatment, lose minimal weight, lack sustained weight loss, and engage in the well-known "YoYo" diet phenomenon. While bariatric surgery is currently the only effective treatment for obesity, there are several barriers associated with it such as eligibility requirements, invasiveness, difficult recovery, and cost making it not readily available for everyone. Some approved medications that help with obesity, such as orlistat, lorcaserin, or naltrexone-bupropion, have not been widely adopted by providers or patients due to their limited responses and adverse side effects. Probiotic cocktails have shown to be safe with little to no side effects. Preclinical models of probiotics demonstrate the ability to curb obesity in animal models. Therefore, a probiotic that is able to show significant weight loss along with lifestyle modifications would be highly adopted and desirable.

03

Conditions studied

  • Obesity
  • Food Addiction

Keywords

  • Probiotic
  • Dietary Supplement
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18-50
  • 25-40
  • Male and Female
  • Not Pregnant or Nursing

Exclusion criteria

Exclusion Criteria:

  • Co-morbidities including but not limited to:
  • Type 1 (insulin dependent) diabetes
  • vascular disease
  • drastic weight loss (more than 10lbs over the preceding 2months)
  • frequent strenuous exercise (i.e. marathon runners/heavy weight lifting)
  • abdominal surgeries including weight loss surgery or partial/complete resection of stomach or bowel
  • untreated thyroid disease
  • neurological disease
  • Major medical condition the PI/MD feels would put the subject at risk or interfere with data collection.
  • Chronic pain
  • Diagnosed DSM IV active psychiatric illness including eating disorders. Must not be active or present for at least 2 years. Participants with a positive endorsement on the MINI+ will be excluded.
  • Using medications known to affect hunger/satiety/appetite
  • Pregnant, lactating, postpartum less than 6months.
  • Women of who are not practicing or are planning to get pregnant during the study.
  • Use of oral/IV antibiotics within the last 3 months
  • Use of probiotics in the last 3 months.
  • Heavy use of alcohol and drugs will be determined by a positive endorsement on the MINI+. If the MINI+ is positive for alcohol or drug dependence or abuse, the participant will be excluded. In regards to tobacco use, participants will be excluded if they smoke more than 1/2 pack per day.
  • Cannabis use will not be exclusionary. If the MINI+ is positive for drug dependence or abuse, the participant will be excluded.
  • Significant change in usual diet and/or weight loss of more than 10lbs in the last 2 months.
  • Anyone taking medicines on the medication exclusion list.
  • Non-English Speakers (due to the use of validated questionnaires and limited availability of translated copies, participants must be fluent in English so that they will be able to read and follow directions easily.
  • Maintenance pharmacotherapies will not be exclusionary so long as they have been on a stable dose for 6months.
  • Body weight at enrollment greater than 400lbs.
  • Exclude from Optional MRI if: participant is unable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, metallic foreign bodies, etc.).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Active comparator
    Probiotic

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    Dietary Supplement taken once daily for 3 months (90 days).

  • Dietary supplementPlacebo

    Dietary Supplement taken once daily for 3 months (90days).

06

What researchers measure

Primary outcomes

  1. Differences in metabolite concentrations pre & post intervention - Stool

    Measurement of metabolomics via stool specimen.

    Time frame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).

  2. Differences in metabolite concentrations pre & post intervention - Blood

    Measurement of metabolomics via blood specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).

  3. Differences in microbiome levels pre & post intervention - Stool

    16S RNA sequencing to measure microbiome levels via stool specimen.

    Time frame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).

  4. Differences in microbiome levels pre & post intervention - Blood

    16S RNA sequencing to measure microbiome levels via blood specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).

  5. Differences in microbiome levels pre & post intervention - Stool

    Shotgun metagenomics, sequencing to measure microbiome levels via stool specimen.

    Time frame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (week 6), and once at the final 3month appointment (week 12).

  6. Differences in microbiome levels pre & post intervention - Blood

    Shotgun metagenomics, sequencing to measure microbiome levels via blood specimen.

    Time frame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (week 6), and once at the final 3month appointment (week 12).

Secondary outcomes

  1. Differences in Subjective Stress Response - PANAS

    Between and within group differences on the negative affect subscale from the Brief Positive Affect and Negative Affect Scale (PANAS) before and after the laboratory stress tasks. PANAS scores can range from 10-50 for both the positive and negative affect, with the lower scores representing lower levels of positive/negative affect, and higher scores representing higher levels of positive/negative affect.

    Time frame: Lasting approximately 10 minutes, measured pre & post the laboratory stress tasks, at baseline (week 0) and end of study (week 12).

  2. Changes in Autonomic Measures - Heart Rate Variability

    Between and within group differences in overall average change in heart rate variability pre and post each laboratory stress task.

    Time frame: Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visits, lasting approximately 1 hour.

  3. Changes in Autonomic Measures - Skin Conductance

    Between and within group differences in overall average change in skin conductance response (SCR) pre and post each laboratory stress task measured using BIOPAC GSR (galvanized skin response) 100C system. Measured in Hz.

    Time frame: Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visit. Lasting approximately 1 hour.

  4. Changes in Autonomic Measures - Diastolic & Systolic blood pressure

    Between and within group differences in overall average change in both diastolic and systolic blood pressure pre and post each laboratory stress task.

    Time frame: Measured throughout each laboratory stress task during the baseline (week 0) and end of study (week 12) visit. Lasting approximately 1 hour.

  5. Differences in Attention/Executive Function - Color Stroop

    Between and within group differences on the time it takes to complete the Color Stroop attention/executive function lab stress task.

    Time frame: Lasting approximately 10minutes, measured at baseline (week 0) and end of study (week 12).

  6. Differences in Attention/Executive Function - Trails A & B

    Between and within group differences on the time it takes to complete the Trails A \& B attention/executive function lab stress task.

    Time frame: Lasting approximately 10minutes, measured at baseline (week 0) and end of study (week 12).

  7. Differences in Emotional Arousal System - IAPS task

    Between and within group differences in valence and emotional arousal ratings during the International Affective Picture System (IAPS) task.

    Time frame: Lasting approximately 15minutes, measured at baseline (week 0) and end of study (week 12).

  8. Systolic and Diastolic Blood Pressure

    Measurement of the pressure of circulating blood at rest

    Time frame: Measured three times, once at each in-clinic appointment (week 0, week 6, week 12).

  9. Anthropometrics - BMI

    Measurement of height(in) \& weight(lbs), used to calculate body mass index (BMI).

    Time frame: Measured three times, once at each in-clinic appointment (week 0, week 6, & week 12)

  10. Questionnaire Data - Diet

    Use of validated surveys including the Food Frequency questionnaire, Food Choice Questionnaire.

    Time frame: Self-Reported by the participant at home, collected 3 times (1) before beginning the dietary supplement, (2) at least 1 week before the mid-study appointment, and (3) within 1 week of finishing the 90-day dietary supplement.

  11. Questionnaire Data

    Use of validated surveys to assess ingestive behaviors, stress, health, physical activity, etc.

    Time frame: Self-Reported by the participant at home, collected 3 times (1) before beginning the dietary supplement, (2) at least 1 week before the mid-study appointment, and (3) within 1 week of finishing the 90-day dietary supplement.

  12. Anthropometrics - waist and hip circumference

    Measurement of waist and hip circumference (cm).

    Time frame: Measured three times, once at each in-clinic appointment (week 0, week 6, & week 12)

Other outcomes

  1. Differences in Multimodal Brain Signatures

    Neuroimaging of a subset of participants brain via magnetic resonance imaging (MRI) procedure.

    Time frame: Optional - Measured twice, once at baseline (week 0) and once at end of study (week 12) visit. Lasting approximately 1.5hours.

07

Study locations

1 site
  • University of California
    Los Angeles, California 90095, United States
08

References and documents

Individual participant data

Plan to share: No — At this time there is no plan to make the de-identified data available for sharing with other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Feb 2026, 31 months.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 31 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Dec 2026 → Feb 2026 and completion Jul 2027 → Feb 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2023
First posted
Sep 11, 2023
StartActual
Jul 18, 2023
Primary completionActual
Feb 19, 2026was Dec 2026
CompletionActual
Feb 19, 2026was Jul 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 9, 2026
Primary completion
Dec 31, 2026→Feb 19, 2026 (actual)
Oct 9, 2026
Study completion
Jul 31, 2027→Feb 19, 2026 (actual)
Oct 9, 2026
Enrollment
100 (estimated)→106 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2026→Feb 19, 2026 (now actual)
    Study completion Jul 31, 2027→Feb 19, 2026 (now actual)
    Enrollment 100 (estimated)→106 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06030362
Responsible party
Arpana Church (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Sep 11, 2023
Start date
Jul 18, 2023
Primary completion
Feb 19, 2026
Completion
Feb 19, 2026
Last update
Oct 9, 2026

Study contacts

Arpana Gupta, PhD
principal investigator · The Regents of the University of California, Los Angeles
Tien Dong, MD, PhD
principal investigator · The Regents of the University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion